Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
PURPOSE:Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy. We retrospectively examined the treatment outc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5967753?pdf=render |
| _version_ | 1818296128725057536 |
|---|---|
| author | Shintaro Maru Hideki Uchino Takahiro Osawa Satoshi Chiba Gaku Mouri Ataru Sazawa |
| author_facet | Shintaro Maru Hideki Uchino Takahiro Osawa Satoshi Chiba Gaku Mouri Ataru Sazawa |
| author_sort | Shintaro Maru |
| collection | DOAJ |
| description | PURPOSE:Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy. We retrospectively examined the treatment outcomes of patients with prostate-specific antigen recurrence who underwent radical prostatectomy at our department. MATERIALS AND METHODS:Of the 690 patients who underwent radical prostatectomy for local prostate cancer between 1988 and 2011, 129 patients who received androgen deprivation therapy for prostate-specific antigen recurrence were included in this study. Patient characteristics, luteinizing hormone-releasing hormone agonist administration, and outcomes were compared between the intermittent androgen deprivation group (n = 66) and the continuous androgen deprivation therapy group (n = 63). The non-recurrence and overall survival rates were compared between groups. RESULTS:Thirty-six patients (27.9%) experienced recurrence after luteinizing hormone-releasing hormone agonist administration. The 5-year non-recurrence rate and 10-year overall survival rate were higher in the intermittent group (92.9%) than in the continuous group (92.9 vs 57.9%, P < 0.001; and 95.9% vs 84.3%, P = 0.047, respectively). Furthermore, 63 patients (48.8%) showed a PSA nadir of less than 0.01 ng/mL after initiation of luteinizing hormone-releasing hormone agonist; among these patients, the non-recurrence rate was significantly higher in the intermittent androgen deprivation group (P = 0.003). CONCLUSIONS:Intermittent androgen deprivation therapy for prostate specific antigen recurrence after radical prostatectomy contributed to improvement of the non-recurrence rate and overall survival, and can be considered an effective therapy for better prognosis. |
| first_indexed | 2024-12-13T03:58:37Z |
| format | Article |
| id | doaj.art-8ea705f198de4c5e9f59ff404df4cc59 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T03:58:37Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8ea705f198de4c5e9f59ff404df4cc592022-12-22T00:00:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019725210.1371/journal.pone.0197252Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.Shintaro MaruHideki UchinoTakahiro OsawaSatoshi ChibaGaku MouriAtaru SazawaPURPOSE:Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy. We retrospectively examined the treatment outcomes of patients with prostate-specific antigen recurrence who underwent radical prostatectomy at our department. MATERIALS AND METHODS:Of the 690 patients who underwent radical prostatectomy for local prostate cancer between 1988 and 2011, 129 patients who received androgen deprivation therapy for prostate-specific antigen recurrence were included in this study. Patient characteristics, luteinizing hormone-releasing hormone agonist administration, and outcomes were compared between the intermittent androgen deprivation group (n = 66) and the continuous androgen deprivation therapy group (n = 63). The non-recurrence and overall survival rates were compared between groups. RESULTS:Thirty-six patients (27.9%) experienced recurrence after luteinizing hormone-releasing hormone agonist administration. The 5-year non-recurrence rate and 10-year overall survival rate were higher in the intermittent group (92.9%) than in the continuous group (92.9 vs 57.9%, P < 0.001; and 95.9% vs 84.3%, P = 0.047, respectively). Furthermore, 63 patients (48.8%) showed a PSA nadir of less than 0.01 ng/mL after initiation of luteinizing hormone-releasing hormone agonist; among these patients, the non-recurrence rate was significantly higher in the intermittent androgen deprivation group (P = 0.003). CONCLUSIONS:Intermittent androgen deprivation therapy for prostate specific antigen recurrence after radical prostatectomy contributed to improvement of the non-recurrence rate and overall survival, and can be considered an effective therapy for better prognosis.http://europepmc.org/articles/PMC5967753?pdf=render |
| spellingShingle | Shintaro Maru Hideki Uchino Takahiro Osawa Satoshi Chiba Gaku Mouri Ataru Sazawa Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. PLoS ONE |
| title | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. |
| title_full | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. |
| title_fullStr | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. |
| title_full_unstemmed | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. |
| title_short | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. |
| title_sort | long term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
| url | http://europepmc.org/articles/PMC5967753?pdf=render |
| work_keys_str_mv | AT shintaromaru longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT hidekiuchino longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT takahiroosawa longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT satoshichiba longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT gakumouri longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT atarusazawa longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy |